Overview

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2023-04-03
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the neoadjuvant therapy efficacy of IBI110 in combination with sintilimab versus sintilimab based on pathologic complete response (pCR) rate in stage IIB (primary tumor > 4 cm ) to IIIB (N2 only) subjects with radically resectable NSCLC.
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.